Author’s response to reviews

**Title:** Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

**Authors:**

Leah M Prentice (Leah.Prentice@vch.ca)
Christian Klausen (klausen@interchange.ubc.ca)
Steve Kalloger (skalloger@mac.com)
Martin Kobel (Martin.Koebel@vch.ca)
Steven McKinney (smckinney@bccrc.ca)
Jennifer L Santos (jsantos@bccancer.bc.ca)
Challayne Kenney (Challayne.Smith@vch.ca)
Erika Mehl (Erika.Mehl@vch.ca)
C. Blake Gilks (Blake.Gilks@vch.ca)
Peter Leung (peleung@interchange.ubc.ca)
Ken Swenerton (kswener@bccancer.bc.ca)
David G Huntsman (dhuntsman@bccancer.bc.ca)
Samuel AJ Aparicio (saparicio@bccrc.ca)

**Version:** 4  **Date:** 21 September 2007

**Author’s response to reviews:** see over
Dear Dr. Phillips,

We have addressed the minor essential revisions as recommended by Dr. Danny Welch. Specifically our revised manuscript addresses; 1) the difference in molecular weights for GPR54 between our group and Muir et al. (2001) in the discussion, and 2) we have also included the Jiang et al (2005) reference in our introduction.

As to the recommendation concerning our statistical analysis, the statistics in our manuscript have been reviewed by Dr. Steven McKinney, who received his doctorate in statistics.

We would like to express our gratitude to Dr. Danny Welch whose diligent and thorough revision of our manuscript has created a more powerful journal article.

Dr. Samuel Aparicio, BM, Bch, PhD, MRCPath
Nan and Lorraine Robertson Chair of Breast Cancer Research, UBC/BCCA

Dr. David Huntsman, MD
BC Cancer Agency, 600 West 10th Avenue
Vancouver V5Z 1L3
Email: dhuntsman@bccancer.bc.ca
Telephone: +1 604 877 6000 x 2148